Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jaguar Animal Health ( (JAGX) ) has provided an announcement.
On June 24, 2025, Jaguar Health, Inc. announced an extension of the maturity date for $2.57 million of convertible promissory notes from its March 2025 bridge financing, now maturing on January 30, 2026. This extension, involving participation from the company’s CEO, board members, and other investors, aims to support Jaguar’s strategic goals, including partnerships for non-dilutive funding and advancing development programs for crofelemer in treating various conditions.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.
Jaguar Animal Health’s overall stock score reflects significant financial challenges and bearish technical indicators, which weigh heavily on the score. While there are promising developments in product trials and strategic corporate actions, these are overshadowed by the company’s high leverage, ongoing net losses, and negative cash flow trends.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company that develops novel proprietary prescription medicines derived from plants in rainforest areas. The company focuses on treating gastrointestinal distress in humans and animals, with products like crofelemer for noninfectious diarrhea in adults with HIV/AIDS and Canalevia for chemotherapy-induced diarrhea in dogs. Jaguar Health operates through its subsidiaries, Napo Pharmaceuticals and Napo Therapeutics, and has a joint venture, Magdalena Biosciences, targeting mental health indications.
Average Trading Volume: 142,276
Technical Sentiment Signal: Sell
Current Market Cap: $3.71M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.